Immunocore Holdings plc provided revenue guidance for the fourth quarter and twelve months ended December 31, 2022. The Company preliminarily estimates that its total net sales were approximately $50 million for the fourth quarter ended December 31, 2022, an increase of approximately 25% compared to the third quarter ended September 30, 2022.
The Company preliminarily estimates that its total net sales were approximately $140 million for the fiscal year ended December 31, 2022.